Quest Diagnostics said this week that Simplexa-branded tests for Epstein-Barr virus and BK virus from Quest's Focus Diagnostics business have been CE marked for distribution to more than 30 European countries.

The test kits, which uses real-time PCR and run on the 3M Integrated Cycler, are intended to aid in the clinical management of immunocompromised patients, Quest said. The cycler is a compact, portable testing platform that can provide results in as little as an hour following sample extraction.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.